Business Description
Compare
Compare
Traded in other countries / regions
6HN.Germany01952.Hong Kong IPO Date
2020-10-09Description
Everest Medicines Ltd is a biopharmaceutical company that integrates licensing, clinical development, and commercialization of potentially globally therapies to address critical unmet medical needs in Greater China and other emerging Asia Pacific markets. The company has assembled a portfolio of eight clinical-stage drug candidates for oncology, immunology, cardio-renal disease, and infectious disease.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.85 | |||||
| Equity-to-Asset | 0.84 | |||||
| Debt-to-Equity | 0.1 | |||||
| Debt-to-EBITDA | -0.39 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 1.31 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -1 | |||||
| 3-Year EPS without NRI Growth Rate | -2 | |||||
| 3-Year FCF Growth Rate | -77.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.88 | |||||
| 9-Day RSI | 44.43 | |||||
| 14-Day RSI | 44.49 | |||||
| 6-1 Month Momentum % | 94.06 | |||||
| 12-1 Month Momentum % | -19.43 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.37 | |||||
| Quick Ratio | 2.36 | |||||
| Cash Ratio | 2.3 | |||||
| Days Inventory | 1103.42 | |||||
| Days Sales Outstanding | 117.14 | |||||
| Days Payable | 89832.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.73 | |||||
| Operating Margin % | -117318.6 | |||||
| Net Margin % | -120086.59 | |||||
| ROE % | -21.5 | |||||
| ROA % | -19.09 | |||||
| ROIC % | -31.13 | |||||
| ROC (Joel Greenblatt) % | -476.63 | |||||
| ROCE % | -20.45 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3775 | |||||
| PB Ratio | 0.79 | |||||
| Price-to-Tangible-Book | 2.19 | |||||
| EV-to-EBIT | -1.96 | |||||
| EV-to-Forward-EBIT | 3.64 | |||||
| EV-to-EBITDA | -2.02 | |||||
| EV-to-Forward-EBITDA | 3.54 | |||||
| EV-to-Revenue | 2354.79 | |||||
| EV-to-Forward-Revenue | 2.91 | |||||
| EV-to-FCF | -1.3 | |||||
| Price-to-Net-Current-Asset-Value | 3.66 | |||||
| Price-to-Net-Cash | 3.85 | |||||
| Earnings Yield (Greenblatt) % | -51.34 |
How Everest Medicines Ltd (HKSE:01952) Makes Its Money
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Annualized Return %
Total Annual Return %
Everest Medicines Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil HK$) | 1.29 | ||
| EPS (TTM) (HK$) | -5.257 | ||
| Beta | 0 | ||
| Volatility % | 137.2 | ||
| 14-Day RSI | 44.49 | ||
| 14-Day ATR (HK$) | 1.724086 | ||
| 20-Day SMA (HK$) | 17.658 | ||
| 12-1 Month Momentum % | -19.43 | ||
| 52-Week Range (HK$) | 5.98 - 30.5 | ||
| Shares Outstanding (Mil) | 309.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Everest Medicines Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||
Everest Medicines Ltd Stock Events
| Event | Date | Price(HK$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Everest Medicines Ltd Frequently Asked Questions
What is Everest Medicines Ltd(HKSE:01952)'s stock price today?
The current price of HKSE:01952 is HK$15.10. The 52 week high of HKSE:01952 is HK$30.50 and 52 week low is HK$5.98.
When is next earnings date of Everest Medicines Ltd(HKSE:01952)?
The next earnings date of Everest Medicines Ltd(HKSE:01952) is .
Does Everest Medicines Ltd(HKSE:01952) pay dividends? If so, how much?
Everest Medicines Ltd(HKSE:01952) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
